Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Payne et al.

Published: 3 November 2021| Version 1 | DOI: 10.17632/fyp26zjgmj.1
Contributors:
,
,
,
,
,
,
,
,
,
,
,
,
PITCH Consortium authors

Description

Overview Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the UK to accelerate population coverage with a single dose. At this time, trial data was lacking, and we addressed this in a study of UK healthcare workers. We aimed to describe the dynamics of T cell and Ab responses after the first dose of BNT162b2 mRNA vaccine over an extended dosing interval, and to compare the magnitude of Ab and T cell responses 4 weeks after dose 2 between short and long vaccination regimens. Human sample and metadata collection HCWs were recruited into the PITCH study at NHS hospitals in five centres in England. All participants received the BNT162b2 Pfizer/BioNTech vaccine at either the "short" dosing interval (3-5 weeks) or "long" dosing interval (6-14 weeks). Peripheral blood was collected and peripheral blood mononuclear cells (PBMCs) and plasma were stored by cryopreservation at -140 oC and -80 oC respectively. Participants were identified as those with samples collected at timepoints of interest (n=589 participants). Long dosing interval accepted timepoints included; - baseline (anytime prior to first dose of vaccine) - 28 days after first vaccine dose (+/- 7 days) - 70 days after first vaccine dose (minimum accepted 40 days. IQR 62/75, range 41 - 129 days), - 28 days after the second vaccine dose (+/- 7 days) - 90 days after the second dose (+/- 7 days) Short dosing interval accepted timepoints included; - baseline (anytime prior to first dose of vaccine) - 7 days after second dose (+ 7days) - 28 days after the second vaccine dose (+/- 7 days) - 90 days after the second dose. Clinical metadata collected included BNT162b2 immunisation dates, date of any prior SARS-CoV-2 infection defined by a positive PCR test and/or detection of antibodies to spike or nucleocapsid protein, presence or absence of symptoms, time between symptom onset and sampling, age, gender and ethnicity of participant. Other metadata included location of study centre. De-identified limited metadata are available here. Options to explore detailed metadata can be sought by contacting the lead author (Paul Klenerman). Data collection Serology and Cellular data were collected from assays using plasma and PBMCs respectively. Serology: MSD and ACE2 assay - Two wells run per test; 1:1000 and 1:10,000 dilution Neutralizing Ab - Serial dilutions were run per test to calculate reduction in number of infected foci - FRNT50 Cellular: ELISpot - Two or three wells run per test ; mean is shown with background subtraction. Total Spike is calculated by adding data from Spike 1 and Spike2 ICS - One run per test compared to positive and negative controls. Results These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective, immunogenic protocol

Files

Steps to reproduce

Software and Algorithms MSD assays: Discovery Bench 4.0. Meso Scale Discovery, Rockville, MD, USA. Immunoassay Analysis Software Meso Scale Discovery IBM SPSS Software 26 IBM https://www.ibm.com ELISpots: AID ELISpot software 8.0 Autoimmun Diagnostika http://www.elispot.com/products/software ICS : Flojo 10.7.1 BD Biosciences https://www.flowjo.com/ FacsCanto II cytometer BD Biosciences, UK Graphs: MSD/ELISpot/Neutralizing Ab/ICS data were prepared for graphs in Prism 8.0 GraphPad https://www.graphpad.com/scientificsoftware/prism/ Multivariate analysis: R version 4.0.4 (2021-02-15) -- "Lost Library Book" Web-based open source software https://www.r-project.org R studio version 1.1.463 Web-based open source software https://www.rstudio.com

Institutions

University of Liverpool, University of Oxford, The University of Sheffield, Public Health England, University of Birmingham

Categories

Vaccine, Immunity, COVID-19

License